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MMP12 counters neutrophil influx, termi-
nates complement activation, acceler-
ates coagulation, and clears NETs of actin
and fibrin to dampen and prepare for the
resolution of inflammation.
Cell Reports
ArticleMacrophage Matrix Metalloproteinase-12 Dampens
Inflammation and Neutrophil Influx in Arthritis
Caroline L. Bellac,1,2 Antoine Dufour,1,2 Michael J. Krisinger,1,3 Anantasak Loonchanta,1,3 Amanda E. Starr,1,5
Ulrich auf dem Keller,1,2 Philipp F. Lange,1,2 Verena Goebeler,1,2 Reinhild Kappelhoff,1,2 Georgina S. Butler,1,2
Leslie D. Burtnick,1,4 Edward M. Conway,1,3 Clive R. Roberts,1,2 and Christopher M. Overall1,2,5,*
1Centre for Blood Research
2Department of Oral Biological and Medical Sciences
3Department of Medicine
4Department of Chemistry
5Department of Biochemistry and Molecular Biology
University of British Columbia, Vancouver, BC V6T 1Z3, Canada
*Correspondence: chris.overall@ubc.ca
http://dx.doi.org/10.1016/j.celrep.2014.09.006
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARY
Resolution of inflammation reduces pathological
tissue destruction and restores tissue homeosta-
sis. Here, we used a proteomic protease substrate
discovery approach, terminal amine isotopic labeling
of substrates (TAILS), to analyze the role of the
macrophage-specific matrix metalloproteinase-12
(MMP12) in inflammation. In murine peritonitis,
MMP12 inactivates antithrombin and activates
prothrombin, prolonging the activated partial throm-
boplastin time. Furthermore, MMP12 inactivates
complement C3 to reduce complement activation
and inactivates the chemoattractant anaphylatoxins
C3a and C5a, whereas iC3b and C3b opsonin cleav-
age increases phagocytosis. Loss of these anti-in-
flammatory activities in collagen-induced arthritis in
Mmp12/ mice leads to unresolved synovitis and
extensive articular inflammation. Deep articular carti-
lage loss is associated with massive neutrophil
infiltration and abnormal DNA neutrophil extracel-
lular traps (NETs). The NETs are rich in fibrin and
extracellular actin, which TAILS identified as
MMP12 substrates. Thus, macrophage MMP12 in
arthritis has multiple protective roles in countering
neutrophil infiltration, clearing NETs, and dampening
inflammatory pathways to prepare for the resolution
of inflammation.INTRODUCTION
The inflammatory response to tissue damage involves a fine
interplay of different pathways and mediators involving the
coagulation cascade, complement system, acute-phase reac-
tants, and innate and adaptive immune cells. This coordinated
process ensures that pathogens and damaged tissue are
removed and healing commenced to restore tissue homeosta-618 Cell Reports 9, 618–632, October 23, 2014 ª2014 The Authorssis. Unresolved inflammation contributes to chronic inflamma-
tory diseases, such as rheumatoid arthritis. Macrophages play
a dominant role in innate immunity (Galli et al., 2011; Geissmann
et al., 2010; Houghton et al., 2009; Marchant et al., 2014). Early
in inflammation, resident macrophages recognize foreign or
damaged material and secrete proinflammatory mediators that
recruit polymorphonuclear neutrophils. Infiltrating neutrophils
phagocytize microorganisms and secrete chemokines. Later,
cell debris and apoptotic neutrophils are cleared by macro-
phage phagocytosis. The influx of neutrophils is partially halted
through chemokine inactivation by matrix metalloproteinase
(MMP) proteolytic processing (Dean et al., 2008) and by
phagocytosis-derived signals (Soehnlein and Lindbom, 2010).
Apoptotic neutrophils display specific efferocytosis ‘‘eat-me’’
signals, whereas nonspecific opsonization by acute-phase reac-
tants, including complement C3b and iC3b, enhances phago-
cytic removal of opsonized material and cells. Macrophage
protease activity is crucial for phagocytosis and proinflammatory
functions, but the in vivo roles of individual macrophage prote-
ases over time in resolving inflammation are unclear.
Whereas MMPs are canonically considered destructive and
proinflammatory, beneficial roles for the macrophage-specific
matrix metalloproteinase-12 (MMP12) in inflammation and im-
munity are known: Mmp12/ mice show exacerbated inflam-
mation in lipopolysaccharide-induced lung inflammation (Dean
et al., 2008) and increased mortality upon bacterial (Houghton
et al., 2009) and viral infections (Marchant et al., 2014). In the
absence of MMP12, development of experimental autoimmune
encephalomyelitis is accelerated and is associated with cytokine
and chemokine dysregulation (Goncalves DaSilva and Yong,
2009). However, MMP12 deficiency reduces neuroinflammation
in aged mice by decreasing the recruitment of bone marrow-
derived microglia to the brain (Liu et al., 2013). Thus, MMP12
can exhibit both proinflammatory and anti-inflammatory activity
in a tissue- or disease context-dependent manner.
Previous studies have focused on the cleavage of extracellular
matrix (ECM) substrates by MMP12 (Gronski et al., 1997). How-
ever, genetic overexpression introduces a protease at non-
physiological levels or in tissues or cells where the protein
is not normally found. In contrast, protease knockout tissues
can be directly compared with wild-type tissues expressing
physiological or pathological relevant amounts of the protease.
Our proteomic technique, terminal amine isotopic labeling of
substrates (TAILS) using iTRAQ isotopic labels, enables sys-
tem-wide analysis of proteolytic events in tissues where all
components are present at relevant levels in vivo (auf dem
Keller et al., 2013) as well as substrate identification of specific
proteases in complex cellular proteomes and secretomes (auf
dem Keller et al., 2010; Kleifeld et al., 2010; Prudova et al.,
2010). Substrates and their cleavage sites are identified by rela-
tive quantification of iTRAQ-labeled N-terminal peptides,
including protease-generated neo-N-termini, by comparing
protease-expressing to protease-null samples by tandem
mass spectrometry (MS/MS).
We report multiple anti-inflammatory roles for MMP12 that are
executed through cleavage of substrates that were identified in a
proteomic screen using TAILS analysis of secretomes from
fibroblasts and TNF-a-treated macrophages incubated with
MMP12, and in peritonitis in Mmp12+/+ versus Mmp12/
mice. Prothrombin was activated by MMP12, and eight com-
plement components were identified as in vivo MMP12 sub-
strates. We show that macrophage MMP12 promotes resolution
of inflammation by cleaving C3 to dampen complement activa-
tion, MMP12 inactivates C3a and C5a chemoattractants to
reduce inflammatory cell infiltration, and together these activities
act in concert with iC3b and C3b cleavage, which increases
phagocytic clearance of apoptotic cells and foreign material.
These anti-inflammatory roles of MMP12 were validated in
collagen-induced arthritis; in the absence of MMP12, arthritis
was severely debilitating with unresolved inflammation and pro-
nounced infiltration of neutrophils consistent with the loss of
MMP12 inactivation of complement. Excessive neutrophil extra-
cellular trap (NET) deposition was found in the joints that con-
tained large amounts of embedded actin and fibrin that are not
normally present (Brinkmann et al., 2004). Thus, we show unex-
pected connections between inflammatory protease pathways
in vivo for macrophage MMP12, which include procoagulant
and anticoagulant roles, as well as the reduction of complement
activation. In addition, MMP12 activity leads to a decrease in
neutrophil infiltration at 18 days, as well as the removal of fibrin
and actin from NETs in inflamed tissue.
RESULTS
Proteomic Identification of New MMP12 Substrates in
Inflammation by TAILS
In comparing wild-type mice with protease-knockout mice, pro-
teins may be cleaved either directly by MMP12 or indirectly by
proteases that are regulated by MMP12 in the wild-type mice.
This can occur following MMP12 cleavage of regulator proteins
(e.g., receptors, inhibitors, and other proteases forming the
protease web) (Fortelny et al., 2014). Therefore, to identify new
biological roles of macrophage MMP12 in inflammation, we
adopted a rigorous and integrated three-system proteomics
approach. To be designated as a high-confidence candidate
substrate, cleaved proteins must be reproducibly identified by
the same neo-N-termini in three separate proteomics analyses
in two different in vitro proteomics analyses of MMP12-cleavedCsecretomes that were also identified in vivo by TAILS analysis
of inflammation models in wild-type and MMP12 knockout
mice. A total of 24 candidates were then confirmed by biochem-
ical cleavage and cell assays.
TAILS identified the MMP12 proteolytic signature after
incubation of murineMMP12with secretomes ofMmp12/mu-
rine embryonic fibroblasts (MEFs) and murine macrophages
(RAW264.7). TheMmp12/MEFs secrete a MMP12-naive pro-
teome enabling high-confidence proteomic substrate discovery
to be performed due to a high signal-to-noise isotopic label ratio.
RAW264.7 macrophages were stimulated with tumor necrosis
factor alpha (TNF-a) to induce expression of inflammation-rele-
vant secreted and plasma membrane proteins. To confirm
biologically relevant substrates of MMP12 in vivo, we winnowed
the in vitro MMP12 substrates by comparison with cleaved pro-
teins identified in peritoneal inflammatory exudates inMmp12+/+
versus Mmp12/ mice. Only cleavage sites and substrates
identified by TAILS in more than one in vitro experiment and
also in vivo were defined as MMP12 substrates.
In the two biological replicates of MMP12-digested MEF
secretomes, we identified 2,974 and 3,230 unique N-terminal
peptides of mature protein N termini and cleaved neo-N-termini
of secretome proteins (Figures 1A and S1A; Table S1A; Supple-
mental Results). TAILS also identified high numbers of N-termi-
nal peptides in duplicates of RAW264.7 cell secretomes treated
with MMP12 (4,490 and 3,363 unique N-terminal peptides) (Sup-
plemental Results; Figure 1A; Table S1B). To discriminate
MMP12 substrates from background cleavage products in the
samples before the assay, we used a statistically determined
isotope ratio cutoff (wild-type [WT]/knockout [KO]) R15 or %
0.06 (auf dem Keller et al., 2010) for substrates in the
RAW264.7 secretomes and R7.3 or %0.13 in the MEF screen
(Supplemental Results; Figures 1A and S1A; Table S1C) using
the software CLIPPER (auf dem Keller and Overall, 2012). In
other words, the cleaved peptides identified by the high iTRAQ
ratios means that in the absence of MMP12, the cleavage prod-
ucts were undetectable. High-ratio MMP12-cleaved neo-N-ter-
minal peptides were also identified in biological replicates of
RAW264.7 secretomes ±TNF-a stimulation using 4plex-iTRAQ
TAILS (Supplemental Results; Figure 1A; Table S1D). Notably,
379 cleavage sites were identical in both the fibroblast and
macrophage secretomes cleaved byMMP12 (Figure 1B). Hence,
these were the highest-confidence substrates having biological
relevance in inflammation (Table 1).
To validate the in vitro findings, we injected 4% thioglycollate
into the peritoneal cavity of Mmp12/ (n = 8) and Mmp12+/+
(n = 8) mice to induce peritonitis on two different background
strains (B10.RIII and 129Sv/Ev). Most cleavage sites were iden-
tified in both mouse strains (Supplemental Results; Table S1E).
Macrophage infiltration was higher in the B10.RIII strain at
96 hr, which was selected for further study in two more replicate
sets of mice (Table S1F). We considered further only the unique
N-terminal peptides from mature protein N termini and cleaved
neo-N termini of 260 proteins that were reproducibly identified
in two or more of three sets of B10.RIII mouse pairs (Table
S1G). Of the peritonitis proteins, 150 were from major Gene
Ontology (GO) categories that were highly relevant to the inflam-
matory response (e.g. inflammatory mediators, coagulation,ell Reports 9, 618–632, October 23, 2014 ª2014 The Authors 619
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Mascot search (peptides) 1,963 2,427 3,321 2,597 720 362
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Figure 1. Overview of MMP12 Substrate Discovery by TAILS and Biochemical Confirmation of Substrates
(A) Numbers of unique peptides and proteins identified by TAILS proteomics of MMP12-digested secretomes fromMmp12/MEFs, macrophages in vitro, and
peritoneal lavages of thioglycollate-induced peritonitis in Mmp12+/+ and Mmp12/ mice in vivo. All experiments were performed as two biological replicates.
Only peptides identifiedmore than two times were further considered as candidate substrates and only if they exceeded the statistically determined isotopic ratio
cutoffs from MEFs >7.3 or <0.13, macrophages >15 or <0.06, or peritoneal lavagesR1.2 or%0.8 (averaged WT/KO, n = 3).
(B) Venn diagrams of peptide and proteins identified by TAILS.
(C) Biochemical validation of candidate MMP12 substrates. Proteins (left arrow) were incubated with recombinant human (h) or mouse (m) MMP12 at three
enzyme/substrate ratios (1:100 [+], 1:10 [++], and 1:5 [+++]); buffer (), 37C for 1 hr or 16 hr. Digestion productswere separated by 12%–15%SDS-PAGE or 15%
Tris-Tricine gels and silver stained. Right arrow, major cleavage products.complement, phagocytosis, antigen presentation, B and T cell
regulation, and ECM remodeling) (Table 1).
In total, 50% (327) of cleaved proteins were common between
the fibroblast and macrophage secretomes, but only 64 were
identical in peritoneal lavage and cell secretomes, as themajority
of the cleaved proteins in the peritoneal lavage were blood
plasma derived. Thus, 64 identical substrates with 75 identical
cleavage sites were identified by iTRAQ-TAILS both in vitro
and in vivo. Thus, the in vivo cleavages most likely directly re-
sulted from MMP12 (Figures 1B and S1B; Tables S1H and
S1I). From the isotopic ratios and GO categories, 36 of these
were classified as in vivo MMP12 substrates with high relevance
in inflammation (24 of which we validated biochemically),
including the acute response proteins a1-antitrypsin, a2 macro-
globulin, serotransferrin, fibrinogen, albumin, haptoglobin, anti-620 Cell Reports 9, 618–632, October 23, 2014 ª2014 The Authorsthrombin, a2HS-glycoprotein, and eight complement proteins
(Tables 2 and S1J).
PICS Analysis of MMP12 Cleavage Sites
To further confirm direct MMP12 cleavage of candidate sub-
strates in vivo, we determined the P6-P60 cleavage site speci-
ficity of MMP12 in vivo and compared this with the optimal
cleavage site amino acid preferences determined using proteo-
mic identification of cleavage site specificity (PICS) (Schilling and
Overall, 2008). PICS profiles active site amino acid preferences
of purified proteases using denatured proteome-derived peptide
libraries. We found that for the iTRAQ-labeled neo-N-terminal
peptides in vivo having Mmp12 WT/KO ratios R15, the
amino acid preferences matched those obtained in vitro by
PICS (Figure S1C), supporting the finding that proteins with
Table 1. GeneOntology of High-ConfidenceMMP12 Substrates Reproducibly Identified inMMP12-Cleaved Secretomes of Fibroblasts
and Macrophages In Vitro and In Vivo from Peritoneal Lavages
GO category Protein GO category Protein
Stress/
inflammatory
mediators
Alpha-1-antitrypsin 1-2 B cell regulation B-cell receptor-associated protein 31
Alpha-1-antitrypsin 1-4 Purine nucleoside phosphorylase
Alpha-2-HS-glycoprotein Tumor protein D52
Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 Tyrosine-protein phosphatase non-receptor type 6
Aminopeptidase B Immunoglobulin 
regulation
Fc-binding protein 1
Annexin A1 Gm1418 Anti-VIPase light chain variable region
Apolipoprotein-1 Gm1499 Anti-colorectal carcinoma light chain
Beta-2-microglobulin Hemopexin
Ig kappa chain V19-17Chymotrypsin-like elastase family member 1
Immunoglobulin kappa-chainComplement C3
Tyrosine-protein phosphatase non-receptor type 6Coronin-1A
Natural killer cell 
cytotoxicity
Peroxiredoxin-1Extracellular superoxide dismutase [Cu-Zn]
Tyrosine-protein phosphatase non-receptor type 6Fibronectin
Cell death 
regulation
Aminoacyl tRNA synthase complex-interacting multifunctional proteinGlucose-6-phosphate 1-dehydrogenase X
B-cell receptor-associated protein 31Galectin-1
Bis(5'-nucleosyl)-tetraphosphatase [asymmetrical]Granulins
Catenin beta-1Heat shock protein HSP 90-alpha
Heat shock protein HSP 90-beta Clusterin
Hemopexin Elongation factor 1-alpha 2
Macrophage migration inhibitory factor Galectin-1
Mannan-binding lectin serine protease 2 Glutathione peroxidase 1
Mannose-binding protein A Haptoglobin
Peptidyl-prolyl cis-trans isomerase FKBP1A Heat shock 70 kDa protein 1B
Peroxiredoxin-2 Heterogeneous nuclear ribonucleoprotein U
Phospholipase A-2-activating protein Macrophage migration inhibitory factor
Serum albumin NEDD8-activating enzyme E1 regulatory subunit
Tyrosine-protein phosphatase non-receptor type 6 Peroxiredoxin-2
Cell migration Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 Programmed cell death 6-interacting protein
Apolipoprotein-1 Proteasome activator complex subunit 3
Chloride intracellular channel protein 4 Protein disulfide-isomerase A3
Coronin-1A Purine nucleoside phosphorylase
Destrin Reticulon-4
EMAP-II Serine/threonine-protein phosphatase 2A catalytic subunit b isoform
Glutathione peroxidase 1 Serum albumin
Haptoglobin Transitional endoplasmic reticulum ATPase
Myosin-9 Ubiquilin-1
Septin-2 Ubiquitin-conjugating enzyme E2 Z
Serotransferin 14-3-3 protein eta
Blood 
coagulation
Antithrombin-III 40S ribosomal protein S3a
Fermitin family homolog 3 40S ribosomal protein S6
Fibrinogen alpha polypeptide 2 Cytoskeleton 
remodelling
Actin
Histidine-rich glycoprotein Actin-related protein 2/3 complex subunit 1B
Myosin-9 Adenylyl cyclase-associated protein 1
Pleckstrin Alpha-actinin-1
Complement 
system
Complement C3 Alpha-actinin-4
Complement C4 Coronin-1A
Complement C5 Destrin
Complement factor D Drebrin
Complement factor H-related protein F-actin-capping protein subunit alpha-1
Complement factor I F-actin-capping protein subunit beta
Mannan-binding lectin serine protease 2 Fibronectin
Mannose-binding protein A Filamin-A
Phagocytosis Alpha-2-HS-glycoprotein Gelsolin
Calreticulin Glial fibrillary acidic protein
Complement C3 Macrophage-capping protein
Coronin-1C Myosin-9
Mannose-binding protein A Plastin-2
Antigen 
presentation
Beta-2-microglobulin Pleckstrin
Calreticulin Profilin-1
Glutathione peroxidase 1 Radixin
H-2 class I histocompatibility antigen, L-D alpha chain Ran-specific GTPase-activating protein
Monocyte differentiation antigen CD14 Serotransferrin
Proteasome activator complex subunit 1 Spectrin beta chain, brain 1
Proteasome subunit beta type-4 Vimentin
T cell 
regulation
Catenin beta-1 14-3-3 protein eta
Coronin-1A Extracellular 
matrix
remodelling
Amyloid beta A4 protein
Heat shock protein HSP 90-alpha Biglycan
Myosin-9 Collagen alpha-2(V) chain
Peptidyl-prolyl cis-trans isomerase FKBP1A Galectin-3
Peroxiredoxin-2 Periostin
Plastin-2 Renin-receptor
Purine nucleoside phosphorylase Serpin H1
Tyrosine-protein phosphatase non-receptor type 6 Transforming growth factor-beta-induced protein ig-h3
1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma-1
40S ribosomal protein S6
60S ribosomal protein L22
All substrates met the following stringent criteria by having isotope ratios of cleaved neo-N-terminal peptides (MMP12/cont) after cleavage of
secretomes of MEFs: ratio R7.3 or %0.13; macrophages: ratio R15 or %0.06; peritoneal lavages: Mmp12+/+/Mmp12/ ratio R1.2 or %0.8; or
were biochemically validated as MMP12 substrates.neo-N-terminal peptide ratios R15 were direct substrates of
MMP12 in vivo. For proteins with lower iTRAQ ratios, differences
in the heatmaps crept in, and so these proteins may have been
cleaved by other proteases, albeit in a MMP12-dependant
manner. To confirm the high ratio substrates, we incubated 24
of these with MMP12 in vitro and found all to be cleaved, con-
firming our analysis (Figure 1C and later figures).CAcute-Phase and Complement Proteins are MMP12
Substrates
Notable among the in vivo substrates, the acute-phase proteins
haptoglobin, a2HS-glycoprotein, immunoglobulin G (IgG) and al-
bumin were biochemically confirmed as new MMP12 substrates
(Figure 1C). Many of the substrates identified in vivo showed pro-
teolytic ragging or trimming of the new protein termini byell Reports 9, 618–632, October 23, 2014 ª2014 The Authors 621
Table 2. Proteins Identified from N-Terminal Peptides by TAILS in Peritoneal Lavages Collected fromMmp12+/+ andMmp12/ Mice
Process Name IPISubstrate Averaged ratios of neo-N-terminal Start position of neo N-terminal Cleavage site (P1-P1')
peptides (Mmp12 wt/ ko) peptides (P1')
Coagulation Alpha-1-antitrypsin 1-2 * IPI00129755 1.2 377 P-M
Alpha-1-antitrypsin 1-3 IPI00123920 1.0, 0.9 36, 50 K-D, G-D
Alpha-1-antitrypsin 1-4 * IPI00123924 0.6, 1.1 36, 377 K-D,T-Y
Inter alpha-trypsin inhibitor * IPI00119818 0.8 29 A-E
Alpha-2-macroglobulin IPI00624663 0.9, 1.0 706, 708 A-L, A-V
Antithrombin-III * IPI00136642 1.2, 1.6, 2.6 35, 36, 377 G-N, N-P, L-F
Fibrinogen; alpha * IPI00115522 0.7, 0.4, 0.7, 0.8, 1.0 20, 21, 23, 240, 409 T-T, T-D, T-E, K-S, C-S
Kininogen-1 IPI00114958 0.9 389 R-S
Pi16 protease inhibitor 16 IPI00113610 1 30 A-L
Vitamin K-dependent protein C IPI00113750 1.1 199 R-D
Complement Complement C3 * IPI00323624 1.2, 1.2, 0.9 749, 960, 1321 R-S, K-V, R-S
Complement C4 IPI00131091 1.0 953 R-T
Complement factor D * IPI00116945 1.2, 1.4 26, 212 R-I, S-P
Complement factor H-related protein * IPI00121055 0.8 24 G-E
Complement factor I IPI00320675 0.9, 1.0 24, 361 A-S, R-V
Clusterin * IPI00320420 1.2 265 P-A
Plasma protease C1 inhibitor IPI00122977 1 471 R-S
Mannose-binding protein A * IPI00131398 0.8 19 S-S
Fc fragment of IgG binding protein-like * IPI00227522 0.7 48 K-C
Ig kappa chain V19-17 * IPI00137939 1.2 42 G-D
Ig kappa chain variable * IPI00407273 0.3, 1.7, 1.5 20, 21, 23 A-E, C-D, A-E
Ig kappa chain V19-14 * IPI00556799 1.2 57 G-D
Gm1418 Anti-VIPase light chain variable region * IPI00169754 1.2 23 G-E
Gm1499 Anti-colorectal carcinoma light chain * IPI00462809 1.3 23 C-D
VH coding region * IPI00457421 1.3 20 C-E
Acute phase Alpha-2-HS-glycoprotein * IPI00128249 0.7, 0.9, 1.4, 0.9, 0.7, 0.9, 0.7 274, 275, 276, 278, 280, 325, 328 P-A, A-D, D-P, P-A, S-V, G-Q, G-A
Fetuin-B IPI00469387 1.0 35 R-S
Granulins * IPI00124640 0.7, 1.2 279, 361 K-E, S-D
Haptoglobin * IPI00409148 1.0, 1.3 103, 323 R-I, C-A
Hemopexin * IPI00128484 0.9. 1.9, 1.2 93, 153, 334 N-P, E-C, N-N
Histidine-rich glycoprotein * IPI00322304 1.5 30 A-L
Murinoglobulin-1 * IPI00123223 0.7 727 N-D
Serotransferrin * IPI00139788 0.9, 0.8, 0.9, 2.3 332, 358, 574, 638 R-L, N-S, N-L, F-C
Serum albumin * IPI00131695 0.9, 0.9, 1.0, 3.9, 1.1, 0.8, 27, 82, 86, 87, 89, 106, A-H, E-S, N-C, C-D, K-S, R-E, 
0.9, 1.2, 0.9, 1.4, 0.7, 1.4, 107, 108, 148, 149, 155, 160, E-N, N-Y, M-C, C-T, N-P, M-G, 
1.2, 1.7, 0.9, 0.9, 201, 208, 224, 267, S-C, D-G, K-C, N-K, 
0.8, 0.9, 1.1, 1.5, 0.9,  269,  271, 272, 273, 343, E-C, C-H, H-G, D-G, N-Y,  
1.1, 1.0, 1.2, 0.7, 0.7, 414,416, 417, 424, 442, K-T, N-C, C-D, G-E, Q-V,  
0.6, 0.7, 0.8, 0.9, 1.2, 443, 444, 461, 473, 500, V-S, S-T, K-C, C-V, K-C, 
1.0, 1.6, 1.2, 1.3 583, 591, 592, 593 C-C, T-C, C-F, F-S
Transthyretin * IPI00127560 1.4, 1.2, 0.9 23, 25, 26 P-A, G-A, A-G
Actin * IPI00110850 1.3 356 M-W
Gelsolin * IPI00117167 0.4 408 Y-L
ECM Epidermal growth factor receptor * IPI00121190 2.4 23 G-G
Extracellular superoxide dismutase [Cu-Zn] * IPI00114319 0.8, 0.6, 0.6 20, 21, 23 M-S, S-N, P-G
Fibroleukin IPI00310797 0.9 31 E-D
Other Apolipoprotein A-I * IPI00121209 0.7, 1.1, 1.5 32, 184, 201 W-D, R-T, R-L
Apolipoprotein C-I IPI00119676 1.0 29 P-D
Cfhr2 BC026782 protein * IPI00462363 0.8 81 C-E
Cholinesterase * IPI00131168 1.3 28 S-H
Chymotrypsin-like elastase family member 1 * IPI00171983 1.7 17 S-T
Maltase-glucoamylase * IPI00848693 0.8 58 R-T
Peptide ratios of three different Mmp12+/+ (WT) and Mmp12/ (KO) pairs are averaged. Start positions of neo-N-terminal peptides are listed by the
N-terminal P10 amino acid and the position within the protein.
Asterisks (*) represent candidate MMP12 substrates that were defined as described in Figure S1B and Tables S1E–S1G.exopeptidases that wipe evidence of adjacent cleavages. None-
theless, TAILS identified seven of the canonical serine protease
cleavage sites in C3, C4, and factors D and I in the peritoneal in-
flammatory exudate (Figure 2A) (e.g., C3 was processed at the
critical cleavage site 748RYS749 that generates C3a, the anaphy-
latoxin chemoattractant, and C3b). C3b is the cofactor for the C3
convertase (C3bBb) and C5 convertase (C3bBbC3b), which
cleave and activate C3 and C5.
MMP12-dependent cleavage sites in complement were also
identified from the neo-N-terminal peptides having high WT/KO
ratios in the peritoneal lavages (Figure 2A). Reduced amounts
of the factor I-inactivating cleavage of C3b at 1320RYS1321 were
found in the wild-type mice, suggesting reduced factor I activity
in wild-type mice, but not Mmp12/ mice. Indeed, a cleavage
site was found by TAILS in factor I at 360RYV361 in vivo, and
in vitro we found MMP12-cleaved factor I (Figure 2B). Biochem-
ical validation of MMP12 cleavage of these complement proteins622 Cell Reports 9, 618–632, October 23, 2014 ª2014 The Authorsis shown in Figure 2B. C3a and C5a cleavage was further shown
by MALDI-TOF MS (Figure S2A–S2D). Notably, MMP12 cleaved
the physiologically important fragments of C3 (C3a, C3b, and
iC3b; Figure 2B) at 989QYM990 as shown by Edman sequencing.
Factor D was not cleaved by MMP12 (Figure 2B), providing
evidence that MMP12 does not act as a nonspecific protease.
In total, MMP12 cleaved eight components of the complement
system (Figure 2C).
MMP12 Inactivates C3 and the Opsonin C3b to Reduce
Complement Activation
We hypothesized that MMP12 cleavage of C3, C3a, C3b, and
iC3b would alter their bioactivity. Human C3-deficient serum is
unable to recognize and lyse rabbit erythrocytes, as C3 is
required for formation of the C5b-9 membrane attack complex
(Figure 2C). C3-deficient serum was reconstituted with intact
C3, which led to erythrocyte lysis (Figure 2D). MMP12-cleaved
C3 reduced rabbit erythrocyte lysis >2-fold (p < 0.01) (Fig-
ure 2D). Hence, MMP12 inactivates C3 to reduce complement
activation.
We next assessed the ability of MMP12 to cleave the C3b on
cell surfaces. In complement activation, C3 is cleaved to C3b,
which covalently binds and opsonizes target cell surfaces.
C3b also forms the C3 and C5 convertases (C3bBb and
C3bBbC3b) for efficient activation of C3 and C5, respectively,
and target-cell lysis. Immobilization of intact C3b on rabbit
erythrocytes resulted in 85% lysis even in highly diluted (0.015
3) C3-deficient serum (Figure 2E). In contrast, C3b-tagged
cells were significantly protected from complement lysis in
an MMP12-concentration-dependent manner when later incu-
bated in C3-deficient serum (Figure 2E). Indeed, the inactivation
of surface-bound C3b by MMP12 approached the levels of inhi-
bition by the prototypical alternative pathway inhibitors factors
H and I (Figure 2E). Thus, MMP12 cleavage of C3 and sur-
face-bound C3b reduces the proinflammatory activation of
complement and cell lysis.
Cleavage of C3b and iC3b by MMP12 Increases
Phagocytosis
Complement C3b and iC3b are products of C3 that trigger
phagocytosis by binding to complement receptors, mainly CR1
for C3b and CR3/4 for iC3b on macrophages. Addition of C3b
to stimulated THP1 monocytes significantly increased phago-
cytosis of microparticles (Figure 2F). Unexpectedly, MMP12-
cleaved forms of C3b and iC3b were both significantly stronger
mediators of phagocytosis than their intact counterparts (phago-
cytosis index 1.8 versus 1.3 for C3b; 1.4 versus 1.1 for iC3b; p <
0.001). Edman sequencing revealed that the major MMP12
cleavage site in vitro was identical in C3b and iC3b at position
989QYM990. Thus, macrophage MMP12 promotes phagocytosis
of opsonized cells by generating more potent phagocytosis en-
hancers from C3b and iC3b and thereby is predicted to promote
resolution.
MMP12 Cleavage of C3a Abolishes THP1 Receptor
Binding and Calcium Mobilization
The other C3 cleavage product, C3a anaphylatoxin, increases
vascular permeability and is a potent stimulator of leukocyte
chemotaxis upon binding to the G protein-coupled C3a
receptor on a variety of cells, including most leukocytes.
THP1 monocytes challenged with C3a had a higher intracel-
lular calcium flux than cells challenged with the monocyte
chemokine CCL7 (Figure 2G). Notably, MMP12 potently
reduced C3a receptor stimulation as evidenced by a 3-fold
reduction in calcium flux (Figure 2G). Edman sequencing and
MALDI-TOF MS showed that hMMP12 removed the C-terminal
eight amino acids from hC3a at 740RYA741 (Figures S2A and
S2B) and also removed the five C-terminal amino acids from
hC5a (Figures S2C and S2D) at 746DYM747, which also
decreased calcium mobilization (Figure S3E), but to a lesser
extent than for cleaved C3a. Thus, macrophage MMP12
inactivates the neutrophil and macrophage chemotactic C3a
and C5a anaphylatoxins and is predicted to be anti-inflam-
matory by reducing neutrophil and then macrophage infiltration
in vivo.CMMP12 Decreases Neutrophil Recruitment in Arthritis
In Vivo
We assessed the predicted MMP12 termination of proinflamma-
tory complement activation and associated neutrophil and
macrophage infiltration in vivo in a secondmodel of inflammatory
disease. Mmp12/ mice (129Sv/Ev background) were back-
crossed onto the collagen-induced arthritis-susceptible strain
B10.RIII. Collagen-induced arthritis involves autoimmunity to
type II collagen with synovial hyperplasia, neutrophil and macro-
phage infiltration, and cartilage degradation resulting in joint
dysfunction. Normal hind ankle joints in wild-type (n = 15) and
Mmp12/ (n = 14) mice at day 0 showed no differences in paw
edema or histological changes as quantified by a four-point
grading scheme (0–4) (data not shown). All mice developed
clinical and histological features of arthritis after collagen injec-
tion. However, the knockouts exhibited highly significant and
dramatically worse disease and showed significantly increased
hind ankle widths due to edema versus wild-type animals from
day 9 to day 18, when the difference peaked (1.0 mm versus
0.5 mm, p < 0.05) (Figure 3A). Wild-type mice had a histological
inflammation score of 1.5 on day 18 (n = 4), whereas knockout
animals showed a uniformly maximum inflammation score of 4
(n = 4) (Figure 3B). This was clearly evident in the histological
sections comparing the wild-type (Figures 3C, 3D, and S3) and
knockout mice (Figures 3E–3H, S4, and S5). Thus, the loss of
macrophage-specific MMP12 worsened disease.
Histological analysis showed that inflammation in the joints of
Mmp12/ mice at day 18 was associated with extensive tissue
destruction and the tissue architecture was severely disrupted.
Subchondral bone loss was only evident in the knockouts
and was often associated with groups of fibroblastic cells in
the extensive inflammatory pannus (Figures 3E, 3G, S4, and
S5). Toluidine blue O staining revealed extensive loss of glycos-
aminoglycan from the joint surfaces, with loss of metachromatic
staining to 30% of the cartilage depth (Figures 3F, 3H, S4D,
S4G, and S5), which was not evident in wild-types (Figures 3D,
S3, and S5). Notably, cartilage degradation was adjacent the
profound neutrophilic joint effusions in theMmp12/mice (Fig-
ures 3E, 3G, S4A–S4F, and S5).
Strikingly and consistent with our in vivo proteomics analyses
showing inactivation by MMP12 of the chemoattractants C3a
and C5a in vivo and in vitro, neutrophilic inflammation was
virtually absent in the wild-type mice, unlike the knockout mice
(Figures 3K, S4, and S5). Indeed, wild-type mice had very few
infiltrating cells at all except for one animal, and here the inflam-
mation was dominated by macrophages rather than neutrophils
(proportion of stained cells in synovial fields: macrophages, 23%
[WT] versus 7% [KO]; neutrophils, 14% [WT] versus 91% [KO])
(Figures 3K and S7). Consistent with the marked neutrophilia in
the joints of the knockout mice were large intra-articular accu-
mulations of NETs containing prominent neutrophils that were
not observed in the wild-types (Figures 3, 4, S3, and S5), as pre-
sented later.
MMP12 Lyses Fibrin Clots In Vitro and In Vivo
Extracellular fibrin, the terminal product of the coagulation sys-
tem, accumulated prominently in inflamed joints of Mmp12/
mice compared to wild-types (Figures 3I and 3J). MMP12ell Reports 9, 618–632, October 23, 2014 ª2014 The Authors 623
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cleaves fibrinogen (Hiller et al., 2000). Therefore, we investigated
the ability of MMP12 to degrade fibrin. MMP12 lysed fibrin clots
in vitro, significantly reducing the clot absorption at 405 nm (A405)
to 14% by 2 hr. Marimastat, an MMP inhibitor drug, prevented
fibrinolysis (p < 0.01) (Figure S6A).
THP1 monocytic cells that were induced to differentiate to M0
macrophages with phorbol 12-myristate 13-acetate (PMA) (at
which point they release MMP12) dissolved fibrin clots by 33%
at 2 hr and 50% at 4 hr (Figure S6B). The specific MMP12 inhib-
itor RXP 470.1 prevented all THP1-induced fibrinolysis at 2 hr
(p < 0.01) and significantly reduced fibrinolysis at 4 hr (p <
0.01), revealing the relative importance of MMP12 over other
MMPs in the fibrinolytic repertoire of monocytes in vitro and of
neutrophils in vivo.
Primary peritoneal macrophages from Mmp12/ mice were
also significantly less effective (p < 0.01) than those from wild-
typemice in fibrin clot lysis in vitro (Figure 3L). As discussed later,
MMP12 also cleaved fibrinogen, delaying clotting and hence
reducing fibrin generation (Figure S6C). Hence, in the absence
of macrophage MMP12 in vivo, fibrin significantly accumulates
in NETs and in the intra-articular space in collagen-induced
arthritis, revealing the key role of the macrophage and MMP12
in clearing fibrin from inflammatory sites in vivo.
MMP12 Cleaves Actin and Gelsolin, Preventing
Extracellular Actin Polymerization in NETs
We identified multiple MMP12 cleavage sites within actin and
gelsolin by quantitative proteomic comparison of wild-type
versus MMP12-knockout peritonitis samples using TAILS
(Figure 4A; Table 2). MMP12 cleaved these substrates in
in vitro digests, confirming the in vivo data (Figures 4B and
4C). Extracellular actin filaments are severed and scavenged
by the highly abundant plasma gelsolin. Gelsolin consists of six
homologous domains (G1–G6) (Figure 4D), each having different
functions in regard to calcium and actin binding and in regulating
the assembly of actin filaments. Four major MMP12 cleavage
products of gelsolin were identified in vitro (Figure 4C), and
Edman sequencing revealed that cleavage occurred between
the G2 and G3 domains at positions 182 and 282, producing
two fragments consisting of the G1 domain plus the linker and
the G2 plus G3 domains (Figure 4D).Figure 2. MMP12 Reduces Complement Activation and Increases Pha
(A) In vivo cleavage sites within complement proteins identified by TAILS analysis
protease cleavage sites are in red.
(B) Biochemical confirmation of human C3, C3a, C3b, iC3b, C4b, and C5a and fa
white arrows. Loss of intact C4b is shown by red arrows. Proteins were incuba
Tris-Tricine gels and silver stained. Factor D was not cleaved by MMP12.
(C) Complement activation occurs by three pathways (classical, lectin, and alte
cleaves C3 into C3a and C3b and promotes further cleavage of C5 and the fo
Complement proteins marked with a red slash circle were biochemically validate
(D) MMP12 reduces complement activation by C3. C3 was incubated ±MMP12,
(RBCs) incubated in C3-deficient human serum. Percent RBC lysis is expressed
(E) MMP12 cleavage of C3b bound to the RBC membrane inhibits the alternativ
factors H and I. C3-deficient serum was then added and lysis measured: **p%
(F) MMP12 cleavage of C3b and iC3b increases phagocytosis. PMA-stimulated T
with full-length or MMP12-cleaved C3b or iC3b and phagocytic uptake of the bead
more potent mediators of phagocytosis. ***p < 0.001, Mann-Whitney t test.
(G) MMP12 cleavage of C3a reduces C3a receptor activation. C3a triggers dose
CCL7 and that was lost by MMP12 cleavage. *p < 0.05, Mann-Whitney t test.
CTo assess the functional consequences of gelsolin cleavage,
we performed actin polymerization assays. Intact gelsolin nu-
cleates the polymerization of G-actin, resulting in actin-filament
growth that was quantified by an increase in light scatter
(blue plot in Figure 4E). MMP12 abolished the G-actin nucle-
ation activity of gelsolin, preventing actin polymerization (red
plot in Figure 4E). Marimastat reversed the block (Figure S7A).
Intact gelsolin also severs filamentous actin, causing actin
depolymerization that was quantified by a sharp drop in light
scatter upon addition of gelsolin (Figure 4F) and that was also
prevented by marimastat (Figure S7B). Notably, MMP12-
cleaved gelsolin retained actin-severing activity, although it
was reduced. Models of actin polymerization and severing by
gelsolin and the effect of MMP12 cleavage are shown in Fig-
ures S7C–S7F.
The importance of MMP12 in clearing extracellular actin
in the collagen-induced arthritis model was shown in the
Mmp12/ mice, where hematoxylin and eosin (H&E) staining
showed large clot-like accumulations of extracellular actin
that were not present in the wild-type mice (Figures 4G–4I). In
addition to staining the actin cytoskeleton of intact cells, Alexa
488-phalloidin prominently stained extracellular actin in these
clots inMmp12/ mice (Figures 4J and 4K). The large deposits
of filamentous actin were also associated with DNA in NETs as
shown by Hoechst 33358 staining (Figures 4J and 4K). Other
components of the NETs included fibrin, especially in the
knockout mice (Figures 3I and 3J). The predominance of neu-
trophils in the NETs suggests that the DNA and actin were
from lysed apoptotic neutrophils. Actin in NETs is most un-
usual: Brinkmann et al. (2004) specifically pointed out that
NETs are free of actin. Thus, MMP12 removes filamentous
actin from NETs and extracellular deposits in vivo by coordi-
nated actions involving direct cleavage as well as prevention
of actin polymerization by cleaving gelsolin while preserving
its actin-severing abilities.
MMP12 Cleaves Multiple Components of the
Coagulation System
TAILS analysis of peritoneal exudates identified fibrinogen and
antithrombin cleavage products (Figure 5A) in the wild-type,
but not knockout, mice. Murine MMP12 cleavage of murinegocytosis
of peritonitis lavage in wild-type versus knockouts. Known complement serine-
ctors H and I as human MMP12 substrates. C3 cleavage fragments shown by
ted with MMP12 at 37C for 16 hr and analyzed on 12% SDS-PAGE or 15%
rnative,) with all three converging with the generation of C3 convertase. This
rmation of the membrane attack complex (MAC) leading to target-cell lysis.
d as MMP12 substrates.
and the digests were assessed for lytic activity against rabbit red blood cells
relative to 100% lysis in H2O. **p < 0.01, Mann-Whitney t test.
e pathway. C3b-tagged RBCs were incubated with MMP12 or the inhibitory
0.01, ***p% 0.001, Mann-Whitney t test.
HP1 cells were incubated with serum-coated fluorescent 2 mm microparticles
s analyzed by fluorescence-activated cell sorting. Cleaved C3b and iC3b were
-dependent intracellular calcium mobilization that exceeded the response by
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Figure 3. MMP12 Is Protective in Collagen-Induced Arthritis
(A)Mmp12/mice developed more severe hind ankle swelling than wild-type
controls. Increase in ankle width in wild-type (WT) and knockout (KO) mice
after onset (day 0 = 21 days after immunization with bovine type II collagen).
Values are mean ± SEM. *p < 0.05, Mann-Whitney t test.
(B) Scoring of inflammatory infiltration in hind ankle joints at day 18 demon-
strated a maximal score of synovial inflammation in all knockout mice.
626 Cell Reports 9, 618–632, October 23, 2014 ª2014 The Authorsfibrinogen was confirmed by in vitro digestion of human fibrin-
ogen with humanMMP12 (Figure 5B), which reduced clot forma-
tion in vitro (Figure S6C).
Thrombin is the key executor in the coagulation cascade,
cleaving fibrinogen to fibrin (Figure 5C). Inhibitors such as anti-
thrombin tightly control thrombin activity. In the peritoneal la-
vages, TAILS identified antithrombin neo-N-terminal peptides
with isotopic ratios showing cleavage by MMP12 in vivo (Table
2). Edman sequencing of the major fragment generated by
MMP12 cleavage of bovine antithrombin in vitro at 376LYF377
(Figure 5B) confirmed the murine in vivo TAILS data (this
cleavage site is conserved in murine, human, and bovine anti-
thrombin). Whereas thrombin preincubated with intact anti-
thrombin showed no activity against a specific chromogenic
thrombin substrate, MMP12-cleaved antithrombin lost its ability
to inhibit thrombin (Figure 5D). Thus, MMP12 cleaves and inac-
tivates antithrombin by removing the more C-terminal reactive
loop center at R426 and S427.
As well as promoting thrombin activity by inactivating anti-
thrombin, MMP12 removed the propeptide of prothrombin by
precise cleavage at 43RYA44 to generate thrombin, which
was active (Figure 5E). Incubation of MMP12 with thrombin
showed no further cleavage or degradation (Figure 5B).
MMP12 was not as efficient an activator of prothrombin as fac-
tor Xa, but nonetheless, MMP12 is an inflammatory activator of
prothrombin. The activated partial thromboplastin time is a
performance indicator for measuring the efficacy of both the
intrinsic and the common coagulation pathways (Figure 5B).
We found the activated partial thromboplastin time was
significantly prolonged in plasma of Mmp12/ mice (n = 4)
compared to Mmp12+/+ mice (n = 4) (t = 37 s versus 29 s,
p < 0.05) (Figure 5F), uncovering a procoagulation role for
MMP12 in vivo.(C and D) Histological analysis of hind ankle joints at day 18 in wild-type mice
with collagen-induced arthritis. Only mild synovial inflammatory cell infiltration
was seen using hematoxylin and eosin (HE) staining (C) and with no cartilage
damage shown by Toluidine blue O (TBO) staining for proteoglycan (D). C,
cartilage; S, synovial space; BM, bone marrow. High-resolution click to zoom
imaging.
(E and F) Mmp12/ mice with collagen-induced arthritis at day 18 showed
massive inflammatory infiltration (E), including invasion of the joint and marrow
spaces, neutrophil NETs (N), and marked loss of joint architecture and pro-
teoglycan content (F).
(G and H) Neutrophil NETs and neutrophil-rich synovial inflammation were
frequently seen close to the cartilage (G, white arrows) that was associated
with loss of cartilage proteoglycan inMmp12/mice (H). Red bars in (H) show
depth of intact and proteoglycan-depleted cartilage.
(I and J) Immunostaining for fibrin in wild-type (I) andMmp12/ (J) ankle joint
synovial spaces showed fibrin along the synovial lining inWTmice. In knockout
mice, fibrin was in neutrophil-rich effusions andNETs (N) within the joint space.
(K) Inflammatory cell population differences in ankle joints of wild-type and
knockouts. Neutrophil numbers are strongly elevated in synovial inflammation
inMmp12/ mice: 91% neutrophils and 7% macrophages versus wild-types
having 14% neutrophils and 23% macrophages.
(L) MMP12 mediates fibrinolysis. Incubation of fibrin clots with peritoneal
macrophages resulted in clot lysis as shown by the decrease in A405 nm (A405 =
100% at 0 hr). Mmp12/ macrophages were significantly less efficient in
fibrinolysis than wild-types **p < 0.01, Mann-Whitney t test.
(C)–(F), (I), and (J), original magnification3200; scale bar, 100 mm. (G) and (H),
original magnification 3630; scale bar, 30 mm.
DISCUSSION
We identified important regulatory roles for MMP12 and hence
macrophages in inflammation. We did so using a comprehen-
sive proteomic strategy to identify new MMP12 substrates in
inflammation-relevant secretomes from TNF-a-stimulated or
unstimulated macrophages, Mmp12/ MEFs, and in vivo peri-
tonitis samples. Notably, applying multiplex iTRAQ-TAILS to
in vivo samples enabled us to globally examine proteolytic
events and MMP12-dependent cleavages in vivo, where all of
the proteins and their binding partners are present at relevant
concentrations. Proteases rarely act in isolation (Fortelny
et al., 2014). We report regulatory roles for MMP12 in some
of the major proteolytic networks operative in inflammation.
Through highly reproducible identification of specific substrate
cleavage sites that were found both in vitro and in vivo, we re-
vealed that MMP12 dampens several proinflammatory path-
ways that facilitate resolution. By targeting multiple substrates
from each of the complement and coagulation cascades, we
found uncharacterized and unexpected roles for MMP12 in
these processes. The complement cascade leads to potent
proinflammatory actions in early inflammation, but negative
control of the cascade is poorly understood. MMP12 cleaved
and inactivated eight complement components in peritonitis.
By inactivating C3 and the potent leukocyte chemoattractants
C3a and C5a, MMP12 reduced complement activation and
disabled the main complement chemoattractant signals for
recruiting leukocytes. C3 accounts for tissue damage in
arthritis (Wang et al., 2011). Consistent with this, the most
striking result of MMP12 deficiency was found in collagen-
induced arthritis, where dramatically exaggerated inflammatory
responses in vivo were characterized by massive numbers of
infiltrating neutrophils and gross destruction of the cartilage
and endochondral bone despite the absence of MMP12,
a protease traditionally attributed to ECM degradation in
inflammation.
Coagulation was enhanced by activation of prothrombin by
MMP12 and through cleavage and inactivation of antithrombin;
clotting times were significantly prolonged inMmp12/ plasma
compared with normal Mmp12+/+ plasma. Until this report the
only enzyme known to cleave prothrombin to generate thrombin
aside from factor Xa is the lectin-pathway activator, MASP2
(Gulla et al., 2010). The inactivation of antithrombin was yet
another example of the metalloserpin switch that releases the
brake on serine protease cascades as found in vivo for MMP2
in complement activation (auf dem Keller et al., 2013) and for
MMP8 in controlling neutrophil chemotaxis by CXCL5 and inter-
leukin-8 activation (Fortelny et al., 2014). Rather than cleavage in
the reactive center loop, antithrombin is cleaved by MMP12 at
376LYF377, which removes the reactive bond between R426 and
S427 that mediates inhibition of thrombin by antithrombin (Bjo¨rk
et al., 1982). Notably, 376L-F377 is in the hI/s5A loop and serpin
inhibitory control via cleavage at this point, revealing an unex-
pected mechanism for serpin inhibition. Thus, resident macro-
phages may promote blood coagulation early following tissue
injury through release of MMP12.
The biological and regulatory role for MMP12 in inflammation
pathways was revealed from the knockout mice, where pertur-Cbations in inflammatory pathways were grossly observed on
a macroscopic scale, including accumulation of two new
MMP12 substrates, actin and fibrin, and was accompanied by
intense neutrophilia. The large infiltrates of neutrophils in the
inflamed joints of Mmp12/ mice in collagen-induced arthritis
led to a pronounced accumulation of NETs in the extracellular,
intra-articular, and marrow spaces that were abnormal: NETs
in Mmp12/ mice contained large amounts of fibrin and extra-
cellular actin, which are not normally associated with NETs
(Brinkmann et al., 2004). Extracellular actin is a hallmark of
inflammatory cell damage, since it is released upon cell death
and triggers further inflammatory reactions (Erukhimov et al.,
2000). Filamentous actin is removed by a sophisticated actin-
scavenging system involving the abundant plasma gelsolin
and clearance in the liver (Lee and Galbraith, 1992). However,
the critical role of the macrophage and MMP12 in extracellular
actin removal has not been previously reported. We found
that MMP12 cleaved both actin and gelsolin along with other
intracellular proteins (Table 1), adding to the growing list of
cytosolic proteins that are cleaved by MMPs in the extracellular
space (Butler and Overall, 2009b; 2009a; Cauwe and Opdenak-
ker, 2010). Gelsolin was cleaved into different functional
domains that no longer nucleated actin polymerization yet re-
tained actin-severing activity (Figures S7C–S7F), thus revealing
concerted roles for MMP12 in countering extracellular actin
polymerization and in promoting the clearance of filamentous
actin in vivo.
Fibrin deposits in the arthritic joints, a hallmark of early rheuma-
toid arthritis (Raghu andFlick, 2011), were alsomore pronounced
in the MMP12-knockout mice. We found that MMP12 and PMA-
stimulated macrophages rapidly cleared fibrin clots in vitro and
that wild-typemacrophagesweremore effective in fibrin dissolu-
tion ex vivo than those from knockout mice. Together with the
large fibrin deposits in theMmp12/ mice, this reflects the bio-
logical relevance of MMP12 in fibrinolysis in vivo compared to
neutrophil fibrinolytic proteases (e.g., elastase and cathepsin G
secreted from the dense neutrophil infiltrate in Mmp12/
mice). Thrombin-generated fibrin peptides are chemotactic for
monocytes (Richardson et al., 1976), and MMP12 is activated
by thrombin and plasmin (Raza et al., 2000), thus forming a pro-
teolytic pathway for fibrin clearance in vivo.
The complement system consists of more than 35 intact or
split proteins that recognize and promote elimination of foreign
or damaged material, either by opsonization and phagocytosis,
or by lysis. Serine complement proteases are long known to
cleave and activate complement proteins at canonical sites,
seven of which were identified in vivo by TAILS. In addition, we
identified undescribed cleavage sites within C3 and other com-
plement proteins, four of which had neo-N-terminal peptides
with Mmp12 WT/KO isotopic ratios indicative of MMP12 pro-
cessing. C3 is central to all the classical, alternative, and
mannose-binding lectin cascades. We validated the TAILS
data showing that MMP12 cleaved full-length C3, C3a, C3b,
and iC3b in in vitro assays. Although MMP12 also cleaved C4b
and factors H and I, MMP12 is not a nonspecific protease, as
factor D was not cleaved. Thus, MMP12 cleavage of so many
complement proteins indicates the importance of this protease
in downregulating complement. We hypothesized that cleavageell Reports 9, 618–632, October 23, 2014 ª2014 The Authors 627
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Figure 5. MMP12 Substrates in BloodCoag-
ulation and Fibrinolysis Cascades
(A) Cleavage sites identified by TAILS of murine
peritonitis samples. Known mature N termini are in
red. Edman, the N terminus of major cleavage
products in the in vitro cleavage assays were mi-
crosequenced.
(B) Biochemical validation as MMP12 substrates
of human prothrombin, bovine antithrombin, and
human fibrinogen. Active thrombin is not further
cleaved by MMP12.
(C) Schematic of the coagulation and fibrinolysis
cascades consisting of the intrinsic and extrinsic
pathways that merge at the level of thrombin
activation leading to the formation of fibrin clots.
Activated plasmin dissolves fibrin. Red slash
circles are MMP12 substrates among which
substrates (*) were identified here by TAILS and
biochemically validated.
(D) Progress curves of 50 nM active thrombin ac-
tivity using chromogenic substrate S-2238 in the
presence of 500 nM antithrombin (full length) or
500 nM cleaved antithrombin (cleaved).
(E) Thrombin progress curves showing prothrom-
bin activation byMMP12 compared with factor Xa.
(F) Activated partial thromboplastin time was
significantly increased in plasma of healthy
Mmp12/ mice (n = 4, in duplicate). Values are
mean ± SD. *p < 0.05; Mann-Whitney t test.of iC3b and C3b would reduce phagocytosis of opsonized parti-
cles—in fact, the opposite occurred. Cleavage of both iC3b and
C3b byMMP12 increased the uptake of serum-opsonized beadsFigure 4. MMP12 Cleavages of Gelsolin and Actin Prevent Actin Polymerization In Vitro and In
(A) Gelsolin and actin cleavage sites identified by TAILS in MMP12-cleaved secretomes (in vitro) and periton
(B and C) MMP12 cleaves actin (B) and gelsolin (C). Digestion products (red arrows) were separated by 15% T
and silver stained.
(D) Schematic of the six homologous gelsolin domains (G1–G6) processed by MMP12 into the fragments: G
(E) MMP12-cleaved gelsolin loses actin polymerization nucleation activity. Both gelsolin and full-length gelso
filament growth. G-actin was incubated for 10min in gel filtration buffer alone (actin control) or after adding the
the time indicated by the arrow: gelsolin in MMP12 buffer alone (full-length gelsolin) or gelsolin in gel filtration
MMP12 in assay buffer; MMP12 alone with G-actin in assay buffer.
(F) Actin depolymerization assay. The following proteins were added to F-actin at a mol ratio of 1:20 in polym
buffer alone; gelsolin as a control in gel filtration buffer; full-length gelsolin in MMP12 assay buffer; MMP12-cl
assay buffer. The sharp drop of light scattering showed that like the gelsolin control and full-length gelsolin,
activity. Day 18 Mmp12/ animals show unresolved tissue clots that contain extracellular actin, DNA, fibrin
(G–I) wild-type (WT) (G and H) and Mmp12/ (I) ankle joints with H&E staining showed rich accumulation
extracellular only inMmp12/ arthritic joints as DNANETs and that contained prominent neutrophils (white ar
C, cartilage.
(J and K) Hoechst staining showed extracellular DNA (blue) (J). Alexa 488-phalloidin staining revealed extracel
box in (J) showing extensive extracellular actin in arthritis in the knockout mouse (K). Intact cells, including
contained actin in their cytoskeleton.
Original magnification 3400 (G and H) or 3630 (I and J); scale bars represent 25 mm (G and H) and 10 mm (I
Cell Reports 9, 618–632,by THP1 monocytes. Thus, by enhancing
the removal of C3b or iC3b-opsonized
pathogens or apoptotic neutrophils
in vivo, these inflammation resolution
roles of MMP12 are concordant with the
effect of MMP12 in dampening comple-
ment C3 activity.C3a and C5a, which are potent chemotactic agents for eosin-
ophils (C3a), mast cells (C3a and C5a), neutrophils (C5a), and
macrophages (C5a), were processed byMMP12. The C-terminalVivo
itis exudate (in vivo).
ris-Tricine gels (actin) or 12% SDS-PAGE (gelsolin)
1 plus linker, G2-G3, G2, G3, and G4-G6.
lin in MMP12 assay buffer efficiently nucleate actin
following proteins (protein:actin 100:1 mol ratio) at
buffer alone (gelsolin control); gelsolin cleaved by
erization buffer at the time indicated by the arrow:
eaved gelsolin in assay buffer; and MMP12 alone in
MMP12-cleaved gelsolin retained F-actin severing
, and neutrophils.
s of dark blue intracellular material that was now
rows) (see also Figures S6–S8). N, NETs; P, pannus;
lular actin in the NETs (green). Higher-power view of
prominent polymorphonuclear leukocytes (pmnl),
–K).
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octapeptide of C3a triggers activation of the C3a-receptor, and
even removal of just the C-terminal arginine abolishes the bio-
logical activity of C3a (Hoeprich and Hugli, 1986). We found
that MMP12 cleaved C3a to remove eight amino acids from
the C terminus, which decreased calcium mobilization 3-fold in
THP1 monocytes. C5a was also inactivated by C-terminal pro-
cessing to reduce calcium mobilization.
SinceMMP12 inactivatesC3aandC5aandpromotesphagocy-
tosis of C3b-and iC3b-opsonized particles upon cleavage, we hy-
pothesized that MMP12 downregulates inflammatory cell infiltra-
tion to resolve inflammation and prevent ongoing tissue damage.
Indeed, Mmp12/ mice showed significantly greater ankle
swelling than wild-type mice in collagen-induced arthritis at 18
days. Histopathological assessment confirmed massive inflam-
matory cell infiltration. Strikingly, the joints of Mmp12/ mice
contained proportionately far more neutrophils than wild-types,
whereas macrophage numbers were significantly reduced in
Mmp12/ mice (Figure S5) as has been observed previously in
differentmodelsbut attributed to reducedECMdegradation (Gon-
calvesDaSilvaandYong,2009;Shipleyetal., 1996).Notably, overt
inflammation in wild-type mice at day 18 was rare, but when pre-
sent in one mouse, the infiltrate was dominated by macrophages.
Our study shows that in the absence of MMP12, where che-
moattractants including C5a are not cleaved and therefore
remain active, neutrophils are persistently recruited. Also, neu-
trophils may not be cleared as readily by phagocytosis due to
reduced macrophage numbers and reduced cell surface ‘‘eat-
me’’ signals on apoptotic cells. We also demonstrated truncation
of immunoglobulin IgG2B by MMP12, which prevents comple-
ment activation due to impaired binding of the cleaved form to
the Fc receptor, an additional protective effect that is lacking in
Mmp12/ mice. Thus, we suggest that neutrophil infiltration
into the joint space and effusion of active neutrophil proteases,
together with the lack of complement inactivation, is responsible
for the advanced destruction of cartilage and subchondral bone
in the Mmp12/ mice.
Our TAILS proteomics analyses revealed functions for MMP12
as a procoagulant and in dampening the inflammatory response
to favor resolution: MMP12 represses neutrophil infiltration in
tissue, reduces complement activation, prevents extracellular
actin polymerization, and removes actin filaments and fibrin
from NETs to promote homeostasis in vivo. The importance
and beneficial role of MMP12 is highlighted in its absence, where
unresolved inflammation persists and is exacerbated in vivo
in arthritis. The net effect of MMP12 cleavage on several coagu-
lation proteins is to reduce the activated partial thromboplastin
time by thrombin activation and in opening a metalloserpin
switch by inactivation of antithrombin. Hence, these procoagu-
lant activities ofMMP12 exceed the anticoagulant effect of fibrin-
ogen cleavage. Overall, MMP12 is identified as a key mediator
that sets the stage for resolution of inflammation, a role very
different from its traditionally ascribed role in ECM degradation.EXPERIMENTAL PROCEDURES
Secretome and Peritoneal Lavage Preparations
Secretomes (500 mg) prepared from 129SvEv Mmp12/ MEFs and RAW
264.7 macrophages were incubated with active murine MMP12 (5 mg) in630 Cell Reports 9, 618–632, October 23, 2014 ª2014 The Authors50 mM HEPES, 100 mM NaCl, and 5 mM CaCl2 (pH 7.6) at 37
C for 16 hr.
The same volume of buffer containing 1 mM APMA was added to control
secretomes. Male 42-day Mmp12/ and Mmp12+/+ mice on the 129SvEv or
the B10.RIII background (n = 6 for each of the four genotypes) were injected
intraperitoneally with 0.5 ml of sterile 4% thioglycollate. Mice were euthanized
96 hr later, and the peritoneal cavity was washed out with 4 ml sterile PBS.
After centrifugation (400 3 g), the supernatant was treated with 0.5 mM
phenylmethanesulfonylfluoride and 1 mM EDTA and TCA precipitated as
described in Supplemental Experimental Procedures.
Terminal Amine Isotopic Labeling of Substrates and Mass
Spectrometry
MMP12-digested secretome and peritoneal lavage protein samples were de-
natured, reduced, alkylated, and separately labeled with isotopic iTRAQ-label
or CLIP-TRAQ-labels as described in Supplemental Experimental Procedures.
The different isotopic-labeled samples were then combined and trypsinized at
37C for 16 hr. Unblocked unlabeled tryptic peptides were removed by 5-fold
excess of a high-molecular-weight polyaldehyde polymer (Kleifeld et al., 2010)
(http://flintbox.com/public/project/1948/) and the polymer then removed by
ultrafiltration. The unbound N-terminal peptide solution was fractionated by
strong-cation exchange high-performance liquid chromatography and
analyzed by liquid chromatography-MS/MS on a QSTAR XL Hybrid ESI
mass spectrometer (Prudova et al., 2010).
MS2 scans were searched against a mouse International Protein Index (IPI)
protein database by Mascot and X!Tandem as described in Supplemental
Experimental Procedures. Search results were evaluated by the Trans Prote-
omic Pipeline using PeptideProphet for peptide/protein identification and Libra
for quantification of iTRAQ reporter ion intensities. Final data sets included only
peptides with a PeptideProphet probability error rate%5%.
Proteomic Identification of Cleavage Site Specificity, or PICS
Proteome-derived peptide libraries were prepared for in vitro digestion with
MMP12, and the cleaved peptides were N-terminal biotin conjugated for puri-
fication and MS/MS analysis as described previously (Schilling and Overall,
2008). MMP12 cleavage site specificities in vivo and in vivo were displayed
as heatmaps.
Alternative Pathway Complement Activation by MMP12-Cleaved C3
C3 was incubated with 50 nM MMP12 in HEPES-buffered saline, 4 mM CaCl2
at 37C for 16 hr. Cleavage reactions were added to C3-deficient human
serum, and alternative pathway of complement activation was determined
by incubation for 45 min at 37C with 2.5 3 107 rabbit red blood cells
(RBCs) in GVB-M7C1, 2 mM EDTA and hemolysis quantified from the absor-
bance at 405 nm as described in Supplemental Experimental Procedures.
The hemolytic activity of C3-deficient serum could be fully restored by adding
20–40 nM intact C3.
Proteolytic Cleavage of C3b on RBCs by MMP12 and Alternative
Pathway Activation
C3b-tagged RBC (2 3 108 cells) in HBS-C4 were incubated with 0, 1.2, 6.1,
24.2, or 121 nM MMP12; 400 nM factor I or 0, 10, 50, or 400 nM factor I with
2 mM factor H were controls. After 16 hr incubation at 37C, any MMP12 and
cleavage products that were not cell associated were removed by extensive
washes. Nontreated and treated C3b-tagged RBCs (2.75 3 107 RBCs)
were analyzed by hemolysis in C3-deficient serum dependent to determine
activation of the alternative pathway and its inhibition by MMP12 as described
above and in Supplemental Experimental Procedures.
Phagocytosis Assay
To test the effect of C3b and iC3b cleavage by MMP12 on phagocytosis,
human recombinant C3b and iC3b were incubated with human MMP12 at a
molar ratio 10:1 at 37C for 2 hr in the presence or absence of 1 mM marima-
stat. Samples were then added to human serum-coated Fluoresbrite 2 mm
microparticles and incubated with PMA-activated THP1 cells for 1 hr at a final
concentration of 5 mM intact or cleaved C3b or iC3b. Phagocytosis was
analyzed by flow cytometry as described in Supplemental Experimental
Procedures.
Effect of MMP12 Cleavage on Calcium Mobilization by C3a
Intracellular calcium mobilization in response to addition of full-length C3a or
MMP12-cleaved C3a to Fluo-4-loaded THP1 cells was measured by fluorom-
etry (excitation 494 nm, emission 514 nm) for 150 s at 37C followed by addi-
tion of 5 mM ionomycin for 150 s to obtain fluorescence manimum (Fmax) and
20 mM EGTA to obtain fluorescence minimum (Fmin) as described in Supple-
mental Experimental Procedures.
The Role of MMP12 in Collagen-Induced Arthritis
Arthritis was induced by collagen injection in CFA in 49-day old male
Mmp12/ (n = 15) and Mmp12+/+ mice (n = 14) on the B10.RIII background.
Day 0 is defined as 21 days after collagen injection and was typically the
date of onset of arthritis. On day 18, mice were euthanized and hind ankles
were dissected and prepared for histological staining by H&E, toluidine blue
to visualize cartilage matrix and immunostained as described in Supplemental
Experimental Procedures. Standard images were used to score ankle joint
inflammation as adapted from the Krenn scheme (Krenn et al., 2006): no
inflammation with no synovial increase in cellularity (0); moderate increase in
synovial cellularity (1); overt synovial inflammatory infiltrate (2); overt synovial
inflammatory infiltrate plus any inflammatory cells in the synovial fluid (3);
and abundant infiltration of inflammatory cells into synovial space (4).
Actin Polymerization and Depolymerization Assays
G-actin (4 mM) was preincubated for 10 min alone or at a 100:1 molar ratio with
intact or MMP12-cleaved gelsolin in 1.35 ml buffer A (2 mM Tris-HCl, 0.2 mM
ATP, 0.2 mM CaCl2, 0.5 mM DTT [pH 7.6]). Light scattering was monitored at
90 to the incident beam using a Perkin Elmer LS55 Luminescence Spectrom-
eter, following addition of 150 ml 103 polymerization buffer (1 M KCl, 20 mM
MgCl2), at 360 nm excitation and 364 nm emission with 3.5 nM band passes.
Cleavage of gelsolin by MMP12 was performed in 50 mM Tris-HCl, 150 mM
NaCl, and 5mM CaCl2 (pH 7.6) at 37
C for 16 hr, which was then added to
buffer A. Assays were performed in triplicate and the experiment repeated
twice.
For actin depolymerization, G-actin (4 mM) was polymerized by incubation
for 1 hr after addition of polymerization buffer to 13. Test proteins then were
added at a 1:20 mol ratio of protein:actin in a final volume of 1.5 ml. Light scat-
tering was measured as above.
Thrombin Assay
Thrombin activity was quantified at A405 nm after the addition of 100 mM chro-
mogenic substrate (H-D-Phe-Pip-Arg-pNA, Chromogenix) to 50 nM human
thrombin that had been preincubated for 10 min with 2 nM heparin (Iduron) in
20 mM PBS (pH 7.4), 100 mM NaCl, 0.1% Tween 20, and 0.1% BSA at 22C.
Prothrombin activation was assessed by incubating 400 nM prothrombin with
40 nM human MMP12 or 4 nM factor Xa in assay buffer containing 5 mM
CaCl2 at 37
C for 16 hr before the addition of 100 mM thrombin substrate. To
test the effect of antithrombin cleavagebyMMP12, 500nMbovineantithrombin
was incubated with 50 nMhumanMMP12 (or buffer) in 20mMHEPES, 100mM
NaCl, and 5 mM CaCl2 for 16 hr at 37
C, before the addition of thrombin. After
incubation for 30 min, thrombin activity was quantified as above.
Fibrin Clot Formation
A total of 1 nM human thrombin was added to 2.9 mM human fibrinogen in
20 mM HEPES, 100 mM NaCl, 5 mM CaCl2, and 0.01% Tween 20 (pH 7.4)
on ice, and fibrin clot formation was quantified by the increase in A405 nm.
To test the effect of MMP12 on clotting, fibrinogen was preincubated with
MMP12 (or buffer) at a 10:1 mol ratio at 37C, 16 hr before adding thrombin.
Fibrinolysis
After 1 hr fibrin clot formation, hMMP12 (mol ratio 10:1), MMP12 preincubated
withmarimastat (1 mM), or buffer was added in a volume of 5 ml to the fibrin clot,
and the decrease in A405 nm was measured. Peritoneal macrophages were
isolated fromMmp12/ (n = 5) andMmp12+/+ (n = 5) mice 96 hr after thiogly-
collate stimulation as described in Supplemental Experimental Procedures.
Two hours after fibrin clot formation, 1 3 104 wild-type or knockout macro-
phages were added to each well containing fibrin clots (n = 11/condition)Cand incubated for 2 hr or 4 hr. Cells were then removed, and remaining fibrin
clots were fixed by 4% formaldehyde.
Activated Partial Thromboplastin Time
Male Mmp12/ and Mmp12+/+ (B10.RIII background, n = 4 each) mouse
plasma (50 ml) was diluted with 50 ml Hank’s balanced salt solution before
the addition of 50 ml prewarmed partial thromboplastin time reagent (STAGO)
followed by incubation at 37C for 3 min. Clotting was induced by addition of
50 ml prewarmed 25mM CaCl2, and clotting time measured in a STAGO ST4
analyzer. Samples were measured in duplicate.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Results, Supplemental
Experimental Procedures, seven figures, and one table and can be found
with this article online at http://dx.doi.org/10.1016/j.celrep.2014.09.006.
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